Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Read more about Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure Read more about scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Read more about FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Read more about Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Read more about Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Read more about Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Read more about FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Read more about U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Read more about Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program Read more about Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program
